Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
Abstract
OBJECTIVES: We aimed to estimate whether adding oral glucocorticoids to ILD-modifying therapy improves 12-month lung outcomes in systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS: We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc-ILD initiated an eligible ILD-modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone-equivalent dose ≤20 mg/day). Follow-up ended at the visit closest to 12 months within a 9 to 15-month window. The primary outcome was the between-group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. RESULTS: Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD-modifying therapy and 258 (58.2%) received ILD-modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12-month FVC. The adjusted mean difference in FVC change was -2.10 percentage points (95% CI -4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated-weight sensitivity analysis. CONCLUSION: Adding oral glucocorticoids to ILD-modifying therapy was not associated with improved 12-month FVC in SSc-ILD. Secondary outcomes were sparse and should be interpreted cautiously.
Related
- Prognostic role of nailfold videocapillaroscopy in predicting progression in systemic sclerosis-associated interstitial lung disease: a systematic review and narrative synthesis
- Potential adjunct disease-modifying effects of exercise and physical activity in multiple sclerosis: an umbrella review of disease activity/progression, safety, and inflammatory-neurobiomarker evidence
- SEZ6L2 antibody-associated cerebellar ataxia mimicking alcohol-related brain damage - diagnostic challenges and successful treatment with double filtration plasmapheresis and glucocorticoids: a case report
- Unilateral MR-guided laser interstitial thermal therapy thalamotomy for refractory multiple sclerosis tremor: 12-month outcomes in four patients
- Correlative and Live-Cell Imaging of S100B-Promoter-Associated Interstitial Cells from the Cardiac Sinoatrial Node and Valves
BibTeX
@article{salis2026oral,
title = {{Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.}},
author = {Zubeyir Salis and Simona Truglia and Oliver Distler and Gábor Kumánovics and Gianluca Moroncini and David Launay and Silvia Bellando-Randone and Gonçalo Boleto and Nicoletta del Papa and Ana Maria Gheorghiu and Duygu Temiz Karadag and Zguro Batalov and Gabriella Szucs and Michele Iudici},
journal = {Arthritis Care and Research},
year = {2026},
month = nov,
doi = {10.1002/acr.80205},
url = {https://hal.science/hal-05864436v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
AU - Zubeyir Salis
AU - Simona Truglia
AU - Oliver Distler
AU - Gábor Kumánovics
AU - Gianluca Moroncini
AU - David Launay
AU - Silvia Bellando-Randone
AU - Gonçalo Boleto
AU - Nicoletta del Papa
AU - Ana Maria Gheorghiu
AU - Duygu Temiz Karadag
AU - Zguro Batalov
AU - Gabriella Szucs
AU - Michele Iudici
PY - 2026
DA - 2026/11/11
JO - Arthritis Care and Research
DO - 10.1002/acr.80205
UR - https://hal.science/hal-05864436v1
AB - OBJECTIVES: We aimed to estimate whether adding oral glucocorticoids to ILD-modifying therapy improves 12-month lung outcomes in systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS: We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc-ILD initiated an eligible ILD-modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone-equivalent dose ≤20 mg/day). Follow-up ended at the visit closest to 12 months within a 9 to 15-month window. The primary outcome was the between-group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. RESULTS: Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD-modifying therapy and 258 (58.2%) received ILD-modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12-month FVC. The adjusted mean difference in FVC change was -2.10 percentage points (95% CI -4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated-weight sensitivity analysis. CONCLUSION: Adding oral glucocorticoids to ILD-modifying therapy was not associated with improved 12-month FVC in SSc-ILD. Secondary outcomes were sparse and should be interpreted cautiously.
SN - 2151-464X
SN - 2151-4658
ER -